Products for Research Use Only

Methylprednisolone-d3

CAT: 0804-HY-B0260S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0260S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Methylprednisolone-d3 is the deuterium labeled Methylprednisolone. Methylprednisolone is a synthetic corticosteroid with anti-inflammatory and immunomodulating properties. Methylprednisolone improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels[3].
Product Name Alternative
U 7532-d3
UNSPSC
12352211
Target
Autophagy; Glucocorticoid Receptor; Isotope-Labeled Compounds; SARS-CoV
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Autophagy; Immunology/Inflammation; Others; Vitamin D Related/Nuclear Receptor
Field of Research
Cancer; Infection; Endocrinology; Inflammation/Immunology
Solubility
10 mM in DMSO
Smiles
C[C@@]12[C@](CC[C@]2(O)C(CO)=O)([H])[C@@]3([2H])[C@@]([C@H](C1([2H])[2H])O)([H])[C@@]4(C([C@H](C3)C)=CC(C=C4)=O)C
Molecular Formula
C22H27D3O5
Molecular Weight
377.49
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Strupp, M., et al., Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med, 2004. 351 (4) : p. 354-61.|[3]Bracken, M.B., et al., A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med, 1990. 322 (20) : p. 1405-11.|[4]Zhen Xiang, et al. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. Int J Biol Sci 2020; 16 (13) :2382-2391.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported